BLOOD REVIEWS
Scope & Guideline
Empowering research, transforming blood health.
Introduction
Aims and Scopes
- Hematological Malignancies:
The journal covers a wide range of hematological malignancies including leukemia, lymphoma, and myeloma, focusing on their biology, treatment strategies, and patient management. - Coagulation Disorders:
Research on various coagulation disorders, such as hemophilia, thrombocytopenia, and thrombotic conditions, is a key focus, including novel therapeutic approaches and management strategies. - Transfusion Medicine:
Exploration of transfusion practices, adverse reactions, and the evolving landscape of transfusion-related therapies, including the use of blood products and their clinical implications. - Immunotherapy and Targeted Therapies:
Significant emphasis on the development and application of immunotherapies, CAR T-cell therapy, and targeted treatments in hematological disorders, reflecting the shift towards personalized medicine. - Patient-Centered Care:
The journal highlights the importance of quality of life, patient preferences, and shared decision-making in treatment approaches for hematological diseases. - Emerging Technologies:
Coverage of innovative technologies such as artificial intelligence and genomics in the diagnosis and treatment of hematological conditions, aiming to integrate cutting-edge science into clinical practice.
Trending and Emerging
- Gene Therapy and Genetic Modulation:
There is a growing interest in gene therapy as a potential curative approach for various hematological disorders, including sickle cell disease and hemophilia, highlighting advancements in genetic technologies. - Microbiome and Hematology:
Research on the gut microbiome's role in hematological conditions is on the rise, exploring how dysbiosis may impact disease progression and treatment outcomes, indicating a shift towards understanding systemic influences on hematologic health. - Immunotherapy Innovations:
The emergence of novel immunotherapeutic strategies, including bispecific antibodies and checkpoint inhibitors, is a significant trend, reflecting the ongoing transformation in treatment paradigms for hematological malignancies. - Health Equity and Access to Care:
Increasing publications focus on disparities in hematological care, emphasizing the need for equity in access to innovative therapies, particularly among diverse populations. - Patient-Reported Outcomes and Quality of Life:
There is an increasing emphasis on patient-reported outcomes and quality of life measures in research, underscoring the importance of holistic approaches to patient care in hematology. - Artificial Intelligence in Hematology:
The application of artificial intelligence and machine learning in diagnostics, treatment personalization, and monitoring of hematologic diseases is an emerging theme, indicative of the journal's forward-looking approach.
Declining or Waning
- Traditional Chemotherapy Approaches:
With the rise of targeted therapies and immunotherapies, traditional chemotherapy approaches for hematological malignancies are discussed less frequently, as newer treatments gain prominence. - Basic Hematology:
Fundamental topics in hematology that do not directly relate to clinical or translational research are becoming less common, as the journal increasingly favors articles with direct clinical applications or innovative methodologies. - Epidemiological Studies:
While still important, epidemiological studies focusing on rare conditions or those with limited translational impact are less frequently published, as the journal prioritizes studies that offer immediate clinical relevance. - Classic Diagnostic Techniques:
The focus on traditional diagnostic methods is waning in favor of more advanced techniques, such as genomic profiling and machine learning applications in diagnostics. - Older Treatment Modalities:
The exploration of older treatment modalities, particularly those that have been largely replaced by newer therapies, is less common as the field moves toward more effective and innovative treatment options.
Similar Journals
Indian Journal of Hematology and Blood Transfusion
Fostering Collaboration in Hematology and Transfusion MedicineIndian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.
Hematology
Transforming Hematology: Open Access to Tomorrow's DiscoveriesHematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.
Hematology-American Society of Hematology Education Program
Elevating Standards in Hematology EducationHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
Lancet Haematology
Fostering excellence in hematological research and practice.Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.
TRANSFUSION
Advancing the Science of Blood and BeyondTRANSFUSION is a prestigious peer-reviewed journal published by WILEY, dedicated to advancing the field of hematology and transfusion medicine. With an ISSN of 0041-1132 and an E-ISSN of 1537-2995, this journal serves as a vital resource for researchers and professionals alike, delivering high-quality studies and reviews that impact clinical practice and blood management strategies. The journal enjoys a strong reputation, evidenced by its impressive Q1 ranking in hematology and Q2 in both immunology and allergy as of 2023. Covering foundational aspects from 1958 to 2024, TRANSFUSION not only provides valuable insights but also fosters collaboration and innovation in understanding the complexities of blood donation, transfusion practices, and immunological responses. With its significant contributions to the scientific community, this journal is essential for those seeking to stay at the forefront of research and advancements in transfusion science.
VOX SANGUINIS
Unraveling the Complexities of Blood HealthVOX SANGUINIS is a distinguished peer-reviewed journal in the fields of Hematology and Medicine, published by Wiley, a leading academic publisher based in the United Kingdom. With a rich history dating back to its inception in 1952, this journal has consistently provided a platform for innovative research and insightful reviews, advancing the understanding of blood-related disorders and therapies. As evidenced by its robust performance—ranking #57 out of 137 in Scopus for Medicine in Hematology and holding a Q2 classification in both Hematology and miscellaneous Medicine categories—VOX SANGUINIS is recognized for its significant contributions to the scientific community. This journal serves as a vital resource for researchers, professionals, and students alike, fostering knowledge exchange and collaboration within the field. With its ongoing commitment to quality and integrity, VOX SANGUINIS continues to shape the future of hematological research well into 2024 and beyond.
TRANSFUSION AND APHERESIS SCIENCE
Transforming Transfusion Practices with Cutting-edge ResearchTRANSFUSION AND APHERESIS SCIENCE, published by Pergamon-Elsevier Science Ltd, serves as a pivotal platform for researchers and practitioners in the fields of hematology, transfusion medicine, and apheresis. With an ISSN of 1473-0502 and an E-ISSN of 1878-1683, this peer-reviewed journal boasts a respectable Q3 ranking in the Hematology category as of 2023, positioning it within the 45th percentile among its counterparts. Operating from the United Kingdom, it provides comprehensive insights into the latest advancements and methodologies in transfusion practices and apheresis technology, crucial for enhancing patient care and therapeutic strategies. The journal's scope, covering key developments from 1996 to 2024, allows for a deep exploration of historical and emerging trends within the discipline. Moreover, its open access options facilitate widespread dissemination of research findings, fostering collaboration and innovation in the scientific community. For those dedicated to advancing knowledge in hematology, TRANSFUSION AND APHERESIS SCIENCE represents an essential resource, bridging theory and practice in this vital area of healthcare.
HAEMATOLOGICA
Exploring the Depths of Blood Science: A Legacy Since 1947HAEMATOLOGICA, published by FERRATA STORTI FOUNDATION, is a prestigious journal in the field of hematology, recognized for its high impact and contribution to advancing research in this critical area of medicine. With an impressive Q1 ranking in the 2023 category of Hematology and a notable Scopus rank of #12 out of 137, the journal serves as an essential platform for disseminating innovative studies, clinical trials, and comprehensive reviews from 1947 to 2024. Based in Italy, with a commitment to quality and academic integrity, HAEMATOLOGICA fosters collaboration among researchers, practitioners, and students interested in the latest developments and methodologies within hematological science. Although it does not offer open access, the journal ensures that valuable insights are accessible through institutional subscriptions, emphasizing its role in shaping the future of hematologic research.
Blood Research
Unveiling Breakthroughs in Hematology for Global ImpactBlood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.
AMERICAN JOURNAL OF HEMATOLOGY
Leading the Charge in Hematology InnovationAmerican Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.